The litigation centers on claims that PROCEPT misled shareholders regarding its sales of single-use handpieces used in Aquablation therapy. According to the complaint, the company allegedly utilized aggressive late-quarter bulk discount programs to incentivize purchases that far exceeded actual clinical demand. These practices reportedly pulled future sales into the present, creating an illusion of growth while masking a growing surplus of inventory at customer facilities.
PROCEPT BioRobotics Faces Class Action Over Inventory Practices
A federal securities class action lawsuit now targets PROCEPT BioRobotics Corporation following allegations that the medical device maker artificially inflated financial results. Investors who purchased common stock between February 28, 2024, and February 25, 2026, are being urged by Hagens Berman Sobol Shapiro LLP to seek recovery for substantial losses.
Truth began to emerge in August 2025, when the company missed financial estimates, triggering a series of disclosures. By February 2026, PROCEPT admitted that cumulative excess inventory had reached 10,000 units and that U.S. sales had plummeted 30% sequentially. Management subsequently abandoned the discount program, citing the need to optimize field inventory levels. Between August 2025 and February 2026, the company’s share price declined by more than 48%. Hagens Berman partner Reed Kathrein stated the firm is investigating whether the company intentionally pulled forward sales to satisfy investor expectations without sufficient transparency. Investors have until September 22, 2026, to apply for lead plaintiff status.
Comments (0)
No comments yet. Be the first!